UltraGreen combines a fluorescent dye (indocyanine green) with AI to help surgeons monitor blood flow in real time, reducing surgical complications. The dye is safe, long-established, and supported by global regulatory approvals.
Sales have grown from 20,000 vials in 2016 to 1 million in 2024. UltraGreen’s regulatory approvals in 40+ countries and partnerships with medical equipment providers give it an advantage over competitors.
The company is targeting applications like diabetic foot ulcers and lung cancer detection. It plans to lease camera systems to healthcare institutions on a per-procedure model and is expanding its regulatory, sales, and manufacturing capabilities in Singapore.
UltraGreen is considering regional manufacturing and a powder production plant in Singapore, potential fundraising to accelerate market penetration, and remains open to a future IPO, emphasising long-term investors and ASEAN as a key growth market.
